BMO Capital analyst Matthew Luchini raised the price target on Entasis Therapeutics (NASDAQ: ETTX) to $7.00 (from $5.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE